Partial
Needs Revision
Patient Risk:
Low
Summary
The missed-dose note matches the supplied label, but the response incorrectly treats dose and ARISTOTLE details from sections not provided as established by the supplied prescribing information.
Category Scores
Accurate Statements
The missed-dose instruction is accurately summarized in section 2.3: take the missed dose as soon as possible on the same day, resume twice-daily administration, and do not double the dose.
Section 2.3 gives these instructions.
The label does not state an exception for a dose close to the next dose.
Section 2.3 says to take the missed dose as soon as possible on the same day and resume twice-daily administration; it does not specify that exception.
Unsupported Statements
The acute DVT/PE dose claim is supported by section 2.1, which specifies 10 mg twice daily for 7 days, followed by 5 mg twice daily.
The supplied section 2.1 contains no dose recommendation, so this dose and the assertion that section 2.1 specifies it cannot be verified from the supplied prescribing information.
The ARISTOTLE claim is contradicted because section 14.1 describes apixaban versus warfarin, not enoxaparin.
Section 14.1 and ARISTOTLE trial results are not included in the supplied label sections. The provided information does not establish this as a contradiction.
The enoxaparin comparison is associated with other clinical studies, not ARISTOTLE.
The supplied label sections do not provide the clinical-trial comparisons needed to support this statement.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response evaluates claims rather than directly instructing a patient. Its unsupported conclusions could nevertheless make the audit less reliable, particularly for dosing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
The response relies on dosage and clinical-trial details from label sections not supplied for this evaluation.
Suggested Improvement
Limit conclusions to the supplied label text; characterize the dose and ARISTOTLE statements as not verifiable from the provided sections rather than supported or contradicted.